Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-month open-label phase 3b study of ranibizumab 0.3 mg in subfoveal choroidal neovascularization secondary to age-related macular degeneration
2005-005921-73Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2006
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ranibizumab in age-related macular degeneration (AMD) and Subretinal neovascularization, sponsored by Novartis. Primary endpoint: Incidence of ocular adverse events. Started Feb 2006; status: completed.
02
Drugs
ranibizumab
03
Conditions
age-related macular degeneration (AMD)Subretinal neovascularization
Beyond the preview
Go deeper on 2005-005921-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005921-73.